Related Experiment Video
Updated: Apr 24, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Thrombotic and thromboembolic events were not associated with tranexamic acid in three large randomized controlled
Alexandra M P Brito1, James E Kenny, Biswadev Mitra
1Department of Surgery, Oregon Health and Science University, Portland, OR (A.M.P.B., J.E.K.); Department of Surgery, The Queen's Medical Center, Honolulu, HI (A.M.P.B.); Department of Surgery, HealthParners Regions, Saint Paul, MN (J.E.K.); Emergency Services, Alfred Health, Melbourne, Victoria (B.M.); School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria (B.M., S.B., J.L.S.); Department of Surgery, University of Pittsburgh, Pittsburgh, PA (M.D.N.); Australian Capital Territory, College of Health and Medicine, Australian National University, Canberra (R.G.); Department of Surgery, University of Nebraska Medical Center, Omaha, NE (C.D.B.); Molecular Neurotrauma and Hemostasis Group, Monash University, Melbourne, Victoria (R.M.); Department of Surgery, University of Chicago, Chicago, IL (S.R.); Uniformed Services University of the Health Sciences (M.A.S.).
Background:
Thrombotic and thromboembolic events are a common and potentially preventable complication in multitrauma patients, and substantial quality improvement efforts are directed at prevention. The results of several randomized controlled trials (RCTs) related to the association between tranexamic acid (TXA) and thrombotic/thromboembolic events have demonstrated conflicting results. We aimed to address this by examining whether prehospital TXA was associated with higher rates of thrombotic/thromboembolic events in a harmonized data set from three large multicenter RCTs.
Methods:
We analyzed data using a harmonized data set from three RCTs examining the effects of prehospital TXA: The Pre-Hospital Anti-fibrinolytics for Traumatic Coagulopathy and Hemorrhage Study (PATCH trial), Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP trial) and the Prehospital TXA for TBI trial, part of the Resuscitation Outcomes Consortium (ROC trial). Outcomes included deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, stroke, combined venous thrombotic/thromboembolic events (VTE), and combined arterial thrombotic/thromboembolic events. Multivariable regression was used to adjust for TXA administration, sex, age, injury severity score, Glasgow Coma Scale, shock index, and 24-hour red cell transfusion.
Results:
There were no differences in myocardial infarction, stroke, arterial thrombotic/thromboembolic events, DVT, PE, or VTE in patients who were randomized to TXA compared with those who were not. On univariate analysis, rates of PE, DVT and VTE were significantly higher in the PATCH cohort compared with STAAMP and ROC cohorts, but patients in PATCH had significantly higher injury severity scores and chest trauma when compared with those in ROC and STAAMP.
Conclusion:
This multicenter database combining three large RCTs showed that randomization to TXA was not associated with higher rates of arterial and VTE. The higher rates of thrombotic/thromboembolic events observed in the PATCH trial may be explained by higher injury severity as well as protocolized screening. ( J Trauma Acute Care Surg. 2026;101: 48-56. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.).
Level Of Evidence:
Sub-analysis of randomized controlled trials; Level II.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

